Overview

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborators:
Borstkanker Onderzoek Groep
Roche Pharma AG
Treatments:
Carboplatin
Cyclophosphamide
Fluorouracil
Paclitaxel
Pertuzumab
Trastuzumab